View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
5 August, 2021updated 29 Oct 2021 11:17

eTheRNA establishes Hong Kong office

Belgium-based immunotherapy and vaccine company eTheRNA has opened a new office in Hong Kong to expand its presence in China and the wider Asia-Pacific region.

By Naomi Davies

Belgium-based eTheRNA Immunotherapies, a developer of immunotherapy and vaccine products for the treatment of cancer and infectious diseases, has established a new office and subsidiary in Hong Kong. eTheRNA Asia is located in the Sheung Wan area of the city.

The office will support and build on eTheRNA’s growing activities in China and the broader Asia-Pacific region. In particular, eTheRNA Asia will focus on supporting business and investor relations with its strategic partner, China Grand Pharmaceutical and Healthcare.

In a press release, chief executive officer Steven Powell said: “The strategic aim under the Healthy China 2030 plan is to improve cancer care and develop truly innovative oncology drugs in China itself. Through our Chinese investors and partners we have developed strong links with the region and look forward to increasing our activities and contributing to help fulfil this ambition.”

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Data, analysis and deep insights on foreign direct investment delivered to you
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Investment Monitor